BioCentury | Jan 14, 2013
Company News

Immunovative, Immunovative Therapies deal

...2012). Immunovative Inc. announced in November 2012 it had registered a Phase II/III trial of AlloStim...
...Cancer The December 2011 deal included two products in Phase I/II development to treat cancer: AlloStim...
...2011, FDA sent a warning letter to Immunovative Therapies threatening to terminate an IND for AlloStim...
BioCentury | Jun 11, 2012
Clinical News

AlloStim: Phase I/II data

...Immunovative Therapies Ltd. , Shoham, Israel Product: AlloStim Business: Cancer Molecular target: NA Description: IV formulation...
...An open-label, U.S. Phase I/II trial in 42 patients with refractory solid tumors showed that AlloStim...
...Corp.) gained exclusive, worldwide rights to commercialize all products covered by Immunovative Therapies' IP, including AlloStim...
BioCentury | Jan 23, 2012
Company News

Immunovative Therapies, Novo Energies deal

...EU or Thailand. The license includes two products in Phase I/II development to treat cancer: AlloStim...
...with a p-value less than 0.01. Immunovative expects to begin a Phase II/III trial with AlloStim...
...Last September, FDA sent a warning letter to Immunovative threatening to terminate an IND for AlloStim...
Items per page:
1 - 3 of 3